ADHD Medication + Parent Training for ADHD Families
(TPAC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of combining medication with parent training for families managing ADHD. One group of parents will receive a stimulant medication (extended-release mixed amphetamine salts) along with behavioral training, while another group will initially receive only the training. The study aims to determine if this combined approach can improve symptoms in both children and parents. Families with children showing signs of ADHD and parents diagnosed with ADHD might be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on an antidepressant, it must be well-tolerated, unchanged for 30 days, and approved by your doctor for participation. If you have taken stimulant medication for ADHD in the past 30 days, you may not be eligible.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that Behavioral Parent Training (BPT) is safe and effective for families managing ADHD. Studies have found that BPT reduces parenting stress and improves children's behavior without major safety issues. Parents learn skills to help their children succeed at home and in school, which can significantly aid in managing ADHD symptoms.
Research indicates that extended-release mixed amphetamine salts (MAS) are generally well-tolerated by both children and adults with ADHD. Common side effects include trouble sleeping and dry mouth, but these are usually mild. MAS is already approved for treating ADHD, which supports its safety.
Previous research has shown that both treatments in this trial are safe for people with ADHD.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for ADHD because they combine medication and behavioral training in a unique way. Unlike standard treatments that typically focus on either medication or behavioral therapy independently, this approach starts with parent stimulant medication followed by behavioral parent training. If needed, child stimulant medication is introduced next, allowing for a more tailored and potentially effective strategy. This dual focus aims to address ADHD symptoms more comprehensively by involving both parents and children in the treatment process. By doing so, this method could lead to better management of ADHD symptoms and improved family dynamics.
What evidence suggests that this trial's treatments could be effective for ADHD?
Research has shown that behavioral parent training (BPT) effectively reduces ADHD symptoms and related behavior issues in children. Studies indicate that BPT not only alleviates ADHD symptoms but also enhances parenting skills. Meanwhile, extended-release mixed amphetamine salts (MAS) have significantly improved ADHD symptoms. For example, many patients taking MAS experience a noticeable reduction in symptoms, with some studies finding that up to 75% of participants see significant improvement. In this trial, one arm will explore the combination of parent stimulant medication followed by a child treatment strategy involving BPT and potentially child stimulant medication. Another arm will focus on a child treatment strategy with BPT and potentially child stimulant medication, without prior parent stimulant medication. Both BPT and MAS show promising results for managing ADHD symptoms, and using them together might offer even greater benefits.16789
Who Is on the Research Team?
Andrea Chronis-Tuscano, Ph.D.
Principal Investigator
University of Maryland, College Park
Are You a Good Fit for This Trial?
This trial is for parents over 21 with ADHD and their children aged 3-8 who may also have ADHD symptoms. Parents must meet full criteria for ADHD, be in good physical health, not pregnant, and agree to use contraception if applicable. Children should not have been on stimulant medications before or only tried them without success.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Parents receive stimulant medication and behavioral parent training, while children receive behavioral parent training with potential recommendation for stimulant medication
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Behavioral Parent Training
- Extended release mixed amphetamine salts (MAS)
Behavioral Parent Training is already approved in United States, European Union, Canada for the following indications:
- Disruptive Behavior Disorder
- Oppositional Defiant Disorder
- Conduct Disorder
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Anxiety with behavioral difficulties
- Disruptive Mood Dysregulation Disorder (DMDD)
- Intermittent Explosive Disorder (IED)
- Disruptive Behavior Disorder
- Oppositional Defiant Disorder
- Conduct Disorder
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Anxiety with behavioral difficulties
- Disruptive Behavior Disorder
- Oppositional Defiant Disorder
- Conduct Disorder
- Attention-Deficit/Hyperactivity Disorder (ADHD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, College Park
Lead Sponsor
Children's National Research Institute
Collaborator
University of Michigan
Collaborator
Seattle Children's Hospital
Collaborator
National Institute of Mental Health (NIMH)
Collaborator